Trial Profile

A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects With Sickle Cell Disease

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 20 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tovinontrine (Primary)
Indications Beta-thalassaemia; Sickle cell anaemia
Focus Adverse reactions; Therapeutic Use
Acronyms Ardent
Sponsors Imara Inc

Most Recent Events

09 May 2022 Status changed from active, no longer recruiting to discontinued.
20 Apr 2022 This trial has been discontinued in Greece (End date: 6th April 2022) according to European Clinical Trials Database record.
05 Apr 2022 According to an Imara Inc media release, the company has decided to discontinue Ardent and Forte during the second quarter as well as the further development of tovinontrine in sickle cell disease and beta-thalassemia.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com